1CM
CRL icon

1492 Capital Management’s Charles River Laboratories CRL Stock Holding History

1492 Capital Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.76M Sell
7,741
-134
-2% -$23.9K 0.52% 58
2026
Q1 		$1.36M Buy
7,875
+1,816
+30% +$337K 0.52% 58
2025
Q4 		$1.21M Buy
+6,059
New +$1.1M 0.46% 61
2022
Q3 		– Sell
-5,738
Closed -$1.23M – 109
2022
Q2 		$1.23M Buy
5,738
+10
+0.2% +$2.44K 0.81% 42
2022
Q1 		$1.63M Sell
5,728
-69
-1% -$21.3K 0.86% 41
2021
Q4 		$2.18M Hold
5,797
– – 1.08% 33
2021
Q3 		$2.39M Sell
5,797
-78
-1% -$32.4K 1.21% 29
2021
Q2 		$2.17M Hold
5,875
– – 1.11% 33
2021
Q1 		$1.7M Sell
5,875
-153
-3% -$42.5K 0.97% 41
2020
Q4 		$1.51M Buy
6,028
+473
+9% +$113K 0.87% 38
2020
Q3 		$1.26M Buy
5,555
+329
+6% +$68.3K 0.94% 35
2020
Q2 		$911K Sell
5,226
-35
-0.7% -$5.59K 0.78% 39
2020
Q1 		$664K Sell
5,261
-10
-0.2% -$1.5K 0.79% 41
2019
Q4 		$805K Sell
5,271
-18
-0.3% -$2.49K 0.71% 40
2019
Q3 		$700K Sell
5,289
-187
-3% -$25.1K 0.68% 46
2019
Q2 		$777K Sell
5,476
-85
-2% -$11.5K 0.73% 45
2019
Q1 		$808K Sell
5,561
-552
-9% -$72.5K 0.68% 47
2018
Q4 		$692K Sell
6,113
-438
-7% -$54.8K 0.62% 50
2018
Q3 		$881K Buy
6,551
+588
+10% +$72.6K 0.57% 54
2018
Q2 		$669K Buy
+5,963
New +$645K 0.48% 65
2015
Q4 		– Sell
-11,211
Closed -$712K – 120
2015
Q3 		$712K Buy
11,211
+4,409
+65% +$317K 0.51% 50
2015
Q2 		$478K Sell
6,802
-6,825
-50% -$505K 0.3% 81
2015
Q1 		$1.08M Sell
13,627
-1,109
-8% -$81.8K 0.63% 37
2014
Q4 		$938K Buy
14,736
+3,994
+37% +$250K 0.59% 53
2014
Q3 		$642K Buy
+10,742
New +$615K 0.36% 68

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

1492 Capital Management's CRL Position: Q2 2026 in Review

1492 Capital Management reduced its Charles River Laboratories (CRL) stake by 1.7% in Q2 2026, selling an estimated $23.9K and leaving 7,741 shares worth $1.76M. The position accounts for 0.52% of the portfolio, ranked #58.

1492 Capital Management first reported a position in CRL in Q3 2014 and has held it in 25 quarters since. The position peaked at $2.39M in Q3 2021. 569 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • 1492 Capital Management held 7,741 shares of Charles River Laboratories worth $1.76M as of Q2 2026.
  • 1492 Capital Management sold 134 Charles River Laboratories shares in Q2 2026, an estimated $23.9K.
  • Charles River Laboratories made up 0.52% of 1492 Capital Management's portfolio in Q2 2026, its #58 holding.
  • 1492 Capital Management first reported a position in Charles River Laboratories in Q3 2014 and has held it in 25 quarters since.
  • 1492 Capital Management's Charles River Laboratories position peaked at $2.39M in Q3 2021.
  • 569 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on 1492 Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.